GHK-Cu + Epithalon + MOTS-c

Where the name "GHK-Cu + Epithalon + MOTS-c" comes from

This name is a component list, not a term of art. It is community and market usage that Peptide Health Lab neither coined nor endorses, and this page exists because the component list is what people search for.

Nothing in the published literature proposes it. On 1 September 2026 the broadest PubMed query joining all three names, (GHK-Cu OR GHK) AND (epithalon OR epitalon) AND ("MOTS-c"), returned zero records, so there is no paper to attribute an origin to. The closest thing to a documented context is a 2026 narrative review of peptides marketed direct to patients, which covers GHK-Cu and MOTS-c among the compounds it surveys and reports that rigorous human safety data for them are scarce.^[1] There is no origin to report here, only the queries and their counts.

No amounts, ranges, schedules or sequencing appear anywhere below. Where the literature reports a quantity for one of these compounds, it belongs to that compound's own page, described in the species and route of the experiment that produced it.

What's in it and why people combine them

MOTS-c is the component the third slot exists for, and it is the component with the least human evidence of the three. It is a sixteen-residue peptide encoded in the mitochondrial genome that the body makes for itself, whose plasma levels fall with age and that translocates to the nucleus under metabolic stress; a 2022 review collects the mechanistic case and the associations with diabetes, cardiovascular disease, osteoporosis and Alzheimer disease, and frames reversal by treatment as potential.^[4] On 1 September 2026 PubMed returned 253 records for "MOTS-c"[tiab], of which 109 also matched (mice OR mouse OR murine OR rat OR rats), and zero for "MOTS-c" AND "first-in-human".

Epithalon contributes a lifespan result from a mouse cancer model. Female transgenic mice carrying the HER-2/neu breast cancer gene received the tetrapeptide subcutaneously from the second month of life until death; mean lifespan rose 13.5% and maximum lifespan 13.9%, and breast adenocarcinomas and lung metastases were less frequent.^[5] The strain is bred to develop mammary tumours, and the authors attribute the effect to suppression of the transgene. Living longer by getting fewer of the tumours you were engineered to get is a real finding about a cancer model.

GHK-Cu contributes a claim that is one step removed from an organism. The work most often cited for its systemic reach profiled gene expression in sixty-four lung tissue samples from smokers with chronic obstructive pulmonary disease, identified a 127-gene signature of emphysema severity, and then used a gene-expression database to nominate GHK as a compound predicted to reverse that signature — a prediction the authors then tested in cultured fibroblasts.^[6] The human data in that study are an association. The part about GHK is a prediction and a cell experiment.

The rationale for putting the three together is that each is said to act on a different layer of aging biology. Three mechanisms in three systems are three mechanisms in three systems.

What the evidence says about the combination

Every three-way search run on PubMed on 1 September 2026 returned zero records: epithalon AND MOTS-c returned 0; (epithalon OR epitalon OR "Ala-Glu-Asp-Gly" OR AEDG) AND ("MOTS-c" OR MOTSc OR "mitochondrial open reading frame of the 12S rRNA-c") returned 0; (GHK-Cu OR GHK) AND (epithalon OR epitalon) AND ("MOTS-c") returned 0; the same query narrowed with (combination OR combined OR "co-administration" OR "administered together") returned 0; and ("MOTS-c") AND ("copper peptide" OR "copper tripeptide" OR "glycyl-histidyl-lysine") returned 0. ClinicalTrials.gov, searched on the same date for each pair of these compounds as a single intervention, returned zero registered studies.

Only one indexed record intersects any two of the three. GHK-Cu AND MOTS-c returned one result, the 2026 sports-medicine review, which lists both among the peptides being sold direct to patients.^[1] Two identifier-scoped PubMed cross-checks on the same date establish that this is the ceiling rather than a starting point: 41966639[uid] AND (epithalon OR epitalon) returned 0, and 41490200[uid] AND ("MOTS-c" OR MOTSc) — the identifier of the 2026 orthopaedic review that does name epithalon — returned 0. The two reviews that between them mention all three compounds do not overlap, so no single paper in the index names this combination's three components together — let alone administers them.

The third component's human record is the sharpest version of the problem. On 1 September 2026, "MOTS-c"[tiab] AND (humans[mesh] AND (randomized controlled trial[pt] OR clinical trial[pt])) returned five records — four PubMed-typed Randomized Controlled Trial, one typed Clinical Trial and Multicenter Study — covering heat stress during immobilization, exercise in breast cancer survivors, acute endurance exercise, metformin, and outcome prediction in revascularized diabetics. Every one of them measured the peptide as an outcome. A secondary analysis of a randomized exercise trial found that sixteen weeks of aerobic and resistance training raised plasma MOTS-c in non-Hispanic White breast cancer survivors and did not raise it in Hispanic survivors, a split the authors report explicitly.^[2] A trial randomizing nineteen physically active men to repeated heat exposure or a sham during two weeks of calf immobilization found that heat raised circulating MOTS-c and that immobilization itself moved no mitokine level.^[3] Both are honest randomized trials, and a randomized trial of exercise or heat that measures a peptide is not a trial of that peptide.

One public record describes MOTS-c being given to people, and it is a registry entry rather than a result. ClinicalTrials.gov, searched on 1 September 2026, lists an industry-sponsored phase 2a randomized double-blind placebo-controlled study of investigational MOTS-c administered subcutaneously to adults with prediabetes and overweight or obesity, with insulin sensitivity as its efficacy question; it recorded an actual start date of 2 February 2026, was first posted on 1 April 2026, is recruiting, and has posted no results. That is a registration, not a finding.

The combination claim on this page is graded anecdotal because there is nothing to grade. Three literatures that never intersect do not become one literature by being listed together.

Where the evidence is weak

Adding a third component made the evidence base thinner, not thicker. The two-compound version of this combination has at least one review naming both compounds inside a single paragraph. This one has none: the ceiling on co-mention here is two of three, established by identifier-scoped cross-check rather than by inference.

Every component's human data measure something other than the intervention. For MOTS-c the human trials measure endogenous peptide moved by exercise or heat.^[3] For GHK-Cu the human data in the systemic paper are a tissue gene-expression association.^[6] For epithalon the whole-animal result is a transgenic mouse strain. Not one of those is a person receiving the compound and something being measured afterwards.

A mouse result in a cancer-prone strain does not transfer to a healthy adult. The lifespan extension was measured in animals engineered to develop mammary tumours, in an experiment where the tumour-incidence and lifespan findings are the same finding.^[5] What that establishes is an effect on carcinogenesis in that model.

A subgroup split is a result, not a footnote. The exercise trial's MOTS-c increase appeared in one ethnic group and not the other in the same study.^[2] Anyone quoting the increase without the split is quoting half of a published finding — and the quantity being split is the peptide the body makes for itself, which the 2022 review describes as present in plasma at levels that decline with age.^[4]

Nothing addresses three simultaneous unapproved compounds. The searches recorded above returned no published record of what any of these three does in the presence of the other two, or in the presence of prescribed medication. What the literature does say, it says about the compounds one at a time: the 2026 sports-medicine review that covers two of these three states in its own abstract that rigorous human safety data for the unapproved peptides marketed direct to patients are scarce and that there is potential for serious harm to patients.^[1]

Questions to bring to a provider

The useful conversation is not about the combination. It is about which measurable thing is meant to change, and what has been shown to change it in a person.

• The searches recorded above returned no indexed paper naming these three compounds together. What, then, is the reasoning for the third component doing anything the first two do not? A framework for exactly this conversation — how a clinician and a patient discuss peptides marketed direct to patients — is what the 2026 sports-medicine review says it set out to provide.^[1]
• If the interest is in MOTS-c specifically, does it change the calculus that the human trials those searches returned measured the peptide the body already makes? In one of them, sixteen weeks of aerobic and resistance exercise raised plasma MOTS-c in non-Hispanic White breast cancer survivors and did not raise it in Hispanic survivors.^[2]
• The epithalon result comes from a strain engineered to develop mammary tumours, where the lifespan finding and the tumour finding are the same finding. What is it supposed to predict for someone who is not that mouse?^[5]
• Is the athlete in this conversation subject to drug testing, and has that been settled before anything else is discussed? Anti-doping chemists named MOTS-c in print among the substances and targets that might become relevant for future doping controls a decade before the 2026 List named it.^[7]
• What measurement, taken at a fixed interval, would show whether anything changed at all? The one quantity this literature actually tracks is plasma MOTS-c, which the 2022 review describes as declining with age.^[4]

Anti-doping status

One of the three components is prohibited in tested sport at all times, in and out of competition, under the World Anti-Doping Agency Prohibited List in force for 2026:

• MOTS-c: section S4.4.1, metabolic modulators. The List names it under activators of AMP-activated protein kinase, in the words "mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)", inside section S4, which is prohibited at all times. The List states that substances in classes S4.3 and S4.4 are non-Specified Substances, which carries different sanctioning consequences from a Specified Substance. Read from the published 2026 International Standard on 1 September 2026, retrieved through the United States Anti-Doping Agency's prohibited-list page to the WADA-hosted PDF.

GHK-Cu and epithalon are named nowhere in any of the three 2026 documents. Searching the Prohibited List, the Monitoring Program and the Explanatory Note on 1 September 2026 for GHK, copper, glycyl, tripeptide, epithalon, epitalon, pineal and AEDG returned zero occurrences of any of those strings in any of the three. Neither compound is on the 2026 Monitoring Program either — that programme's six entries cover ecdysterone, gonadotrophin-releasing hormone analogues in females under eighteen, hypoxen, a set of stimulants, a set of narcotics, and markers of semaglutide and tirzepatide.

An absence from those documents is a fact about those documents. Section S0 reaches any pharmacological substance not addressed elsewhere on the List and with no current approval by any governmental regulatory health authority for human therapeutic use, and it is written as a criterion with examples rather than as a closed catalogue. No approval for human therapeutic use was found for GHK-Cu or epithalon at any regulator searched on 1 September 2026 — the FDA record for both is a compounding-nomination record, and a nomination is not an approval — so the criterion is what governs, and an athlete subject to testing should raise an unapproved compound with their national anti-doping organization rather than read silence as clearance.

Worth knowing for the component that is listed: MOTS-c was named in the anti-doping analytical literature a decade before the List named it. A 2016 survey of emerging drugs affecting skeletal muscle function and mitochondrial biogenesis — PubMed types it Journal Article and Research Support, not Review — names MOTS-c in its own abstract among the substances and therapeutic targets that might become relevant for future doping controls, and presents electrospray-ionization mass spectra of representatives of those substances and of selected in-vitro-derived phase-I metabolites, reporting that test methods had been established for a subset of them.^[7] That abstract describes no method specific to MOTS-c, and this page claims none. That is what a research paper can properly contribute here: a description of the science and the analytical work. The prohibited status itself was taken only from the List. The List is reissued annually and its sections renumber, so an athlete subject to testing should confirm the current year's list rather than this page.